March 13, 2015

An Alliance for Aging Research survey found that consumers want to maintain nonprescription access to acetaminophen. 

March 10, 2015

The Food and Drug Administration recently published bio-equivalence guidance documents. 

February 3, 2015

Zogenix last week announced that the Food and Drug Administration approved a new formulation of the company's Zohydro ER (hydrocodone bitartrate) extended-release capsules, CII.

January 30, 2015

Janssen Therapeutics on Thursday announced that the Food and Drug Administration has approved its Prezcobix (darunavir 800 mg/cobicistat 150 mg) tablets. The drug is used to treat human immunodeficiency virus in combination with other antiretovirals for treatment-naïve and treatment-experienced adults with no darunavir resistance-associated substitutions, according to the company.

 

January 26, 2015

Purdue Pharma on Monday announced the launch of Hysingla ER (hydrocodone bitartrate) extended-release tablets CII. According to the company, the once-daily drug is the first and only hydocodone product to be recognized by the Food and Drug Administration as having properties that deter misuse and abuse via chewing, snorting and injection.

January 14, 2015

The University of Florida's Pharm.D. program recently released an infographic around the risks associated with acetaminophen use. 

November 20, 2014

Purdue Pharma on Thursday announced that the Food and Drug Administration approved Hysingla ER (hydrocodone bitartrate) extended‐release tablets CII, a once‐daily, single‐entity medication formulated using Purdue’s proprietary extended‐release solid oral platform, Resistec.

October 28, 2014

The Acetaminophen Awareness Coalition on Tuesday kicked off its annual “Double Check; Don’t Double Up” campaign.

October 9, 2014

The Food and Drug Administration earlier this month issued draft guidance with several recommendations for manufacturers of acetaminophen products. 

October 8, 2014

Teva Pharmaceutical Industries on Wednesday announced the initiation of a rolling new drug application submission for hydrocodone bitartrate extended-release tablets.

October 1, 2014

Bayer on Wednesday announced it has completed the acquisition of the consumer care business of the U.S. pharmaceuticals group Merck.

 

September 5, 2014

Purdue Pharma on Thursday shared results from several studies evaluating its investigational pain medication Hysingla ER.

August 25, 2014

Pharmaceutical company Iroko announced today that a new version its anti-inflammatory drug Zorvolex had been approved by the Food and Drug Administration.

July 22, 2014

The Food and Drug Administration has granted tentative approval to Teva Pharmaceutical for abacavir sulfate and lamivudine tablets, according to agency records.

July 17, 2014

Purdue Pharma announced that the Food and Drug Administration approved a new 7.5-mcg/hour dosage strength of Butrans (buprenorphine) transdermal system CIII.

July 17, 2014

About 30% of top-performing OTC drugs today were once prescription-only medications noted Dave Wendland, VP Hamacher Resource Group, on Thursday during a videocast hosted by GMDC titled "Rx-to-OTC: Getting it Right at Retail."

June 26, 2014

The Acetaminophen Awareness Coalition on Thursday released “Acetaminophen: How It’s Used, Preventing Overdose and What We Can Do to Promote Safe Use,” a report and educational resource to drive safe and appropriate use of one of the United States’ most common drug ingredients.

June 17, 2014

Lannett Co. received approval from the Food and Drug Administration for codeine sulfate tablets USP, a schedule II controlled substance, in 15 mg, 30 mg and 60 mg dosage strengths.

May 29, 2014

Depomed on Wednesday announced that the Food and Drug Administration has accepted for filing a new drug application from Mallinckrodt for MNK-155.

April 4, 2014

The National Association of Boards of Pharmacy recommended that pharmacies no longer dispense combination drugs containing more than 325 mg of acetaminophen per dosage unit in light of recent regulatory action.

March 25, 2014

VR1 on Tuesday announced the availability of Ausanil, a new non-prescription homeopathic nasal spray formulated to provide rapid pain relief from severe headaches and migraines with no reported systemic side effects or adverse drug-drug interactions.

March 20, 2014

Purdue Pharma recently announced that a Phase 3 study of an investigational extended‐release formulation of hydrocodone bitartrate met its primary efficacy endpoint by showing that patients with chronic low back pain treated with the once‐daily analgesic agent experienced statistically significant reduction in pain compared with placebo.

March 18, 2014

Mallinckrodt Plc last week announced that the Food and Drug Administration approved Xartemis XR (oxycodone hydrochloride and acetaminophen) Extended-Release Tablets (CII), for the management of acute pain severe enough that it requires opioid treatment.

March 6, 2014

McNeil Consumer Healthcare on Wednesday introduced a new form to the Zyrtec portfolio of allergy-relief products — an oral, dissolvable tablet.